Collegium Pharmaceutical (COLL) Deferred Taxes (2021 - 2026)

Collegium Pharmaceutical has reported Deferred Taxes for 6 years, with the latest figure at -$7.2 million in Q2 2026.

• On a quarterly basis, Deferred Taxes fell 145.54% year-over-year to -$7.2 million in Q2 2026; TTM through Jun 2026 was -$30.3 million, a 35.74% decrease from a year earlier, with the FY2025 full-year figure at -$25.7 million, up 4.31% from the prior year.
• Deferred Taxes was -$7.2 million for Q2 2026 at Collegium Pharmaceutical, down from -$968000.0 in the prior quarter.
• The five-year high for Deferred Taxes was $2.1 million in Q3 2022, with the low at -$12.1 million in Q3 2025.
• Average Deferred Taxes over 5 years is -$4.0 million, with a median of -$3.1 million recorded in 2022.
• The sharpest annual moves came in 2022 and 2024: Deferred Taxes soared 656.23% in 2022, then sank 9491.3% in 2024.
• Over 5 years, Deferred Taxes stood at -$1.1 million in 2022, then soared by 68.65% to -$338000.0 in 2023, then tumbled by 2904.73% to -$10.2 million in 2024, then advanced by 0.83% to -$10.1 million in 2025, then grew by 28.96% to -$7.2 million in 2026.
• The last three Deferred Taxes figures came in at -$7.2 million (Q2 2026), -$968000.0 (Q1 2026), and -$10.1 million (Q4 2025), per Business Quant data.